HSE Drugs Group Recommends Not Covering Skyclarys Cost

Bereaved Cork dad hopes Government will step in following HSE Drugs Group recommendation not to fund Skyclarys

On Tuesday, the group recommended against funding the drug for Friedreich's ataxia, a rare genetic disorder which causes progressive damage to the nervous system.

Treatment for Friedreich's ataxia should not be funded by HSE, drugs group recommends

The HSE Drugs Group made the recommendation following a meeting to consider an application for the reimbursement of Skyclarys.

Treatment for Friedreich’s ataxia should not be reimbursed by HSE, drug group recommends

Disease causes progressive damage to the nervous system with those affected having shorter life expectancy

Sufferers of Friedreich’s Ataxia face major setback as HSE Drugs Group rejects Skyclarys reimbursement

There is still hope as the recommendation will have to go before a meeting of HSE senior management on August 25 for a final decision

HSE Drugs Group recommends not covering Skyclarys cost

The HSE Drugs Group has decided to recommend that the drug Skyclarys, for Friedreich's Ataxia, should not be covered by the HSE.

Nerve Ultrasound Detects Segmental Peripheral Nerve Variability in Friedreich Ataxia

Introduction/Aims: Friedreich’s ataxia (FRDA) is the most common inherited ataxia and is caused by GAA repeat expansions in the FXN gene. With the emergence of disease-modifying therapy, structural biomarkers are increasingly needed. This study aimed to assess periphe...